A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...

The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC. The FDA ...

Merck announced that the Food and drug Administration (FDA) has approved Emend (fosaprepitant dimeglumine) for Injection, for use in combination with other antiemetic agents, to prevent delayed nausea ...

Aprepitant 125mg; per pouch; pwd for oral susp after reconstitution. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors with little or no affinity for ...

Merck & Co’s nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. The 1,000-patient trial ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...

Merck & Co has been given the go ahead in the USA to market its Emend drug to treat nausea and vomiting in patients who undergo surgery, increasing the number of patients eligible to receive treatment ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Oral Emend improved gastroparesis symptoms based on commonly used gastroparesis measures in a ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. EMEND IV contains the active ingredient fosaprepitant dimeglumine.